Immunological studies in recovered COVID-19 patients revealed that a combination of SARS-CoV-2-specific antibodies, memory B cells and CD4 and CD8 T cells are likely to be beneficial in minimizing COVID-19 severity and to achieve clinical short-term protection (6, 7). The gene discussed is CD8A; the disease is COVID-19.